Literature DB >> 23060374

Rare immediate hypersensitivity to rifampicin in a patient with tuberculosis requiring drug discontinuation.

Nima Farah1, Andrew Williams, Michelle Joyce, Graham H Bothamley, K Rajakulasingam.   

Abstract

A 47-year-old Turkish female patient was diagnosed with tuberculosis of the sacro-iliac joints and terminal ileum. She developed a severe adverse drug reaction while taking first-line tuberculosis therapy consisting of isoniazid, pyrazinamide and rifampicin as Rifater and ethambutol. Within 5 min of ingestion she developed pruritic rash, angioedema and breathing difficulties, resulting in an A&E admission. The tuberculosis therapy was discontinued. Intradermal and oral challenge tests for rifampicin were conducted but abandoned early on due to reactions which included audible wheeze, vomiting, throat pain and violent rigours. Clinical manifestations were swiftly treated with appropriate medications. This resulted in a change to the tuberculosis treatment regime, where streptomycin, isoniazid, ethambutol and pyrazinamide were given for 2 months and isoniazid and ethambutol for 12 months. Allergic reactions to rifampicin are rare and should be distinguished from flushing due to pyrazinamide. Prompt diagnosis and treatment by clinicians can be life saving.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23060374      PMCID: PMC4544348          DOI: 10.1136/bcr-2012-006791

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  1 in total

1.  Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.

Authors:  Daphne Yee; Chantal Valiquette; Marthe Pelletier; Isabelle Parisien; Isabelle Rocher; Dick Menzies
Journal:  Am J Respir Crit Care Med       Date:  2003-01-31       Impact factor: 21.405

  1 in total
  2 in total

1.  Case Report: A Case of Type 1 Leprosy Reaction and Dapsone Hypersensitivity Syndrome Complicating the Clinical Course of Multibacillary Leprosy.

Authors:  Jeffrey Craig; Cara MacRae; Rochelle G Melvin; Andrea K Boggild
Journal:  Am J Trop Med Hyg       Date:  2019-05       Impact factor: 2.345

2.  Immediate type hypersensitivity and late phase reaction occurred consecutively in a patient receiving ethambutol and levofloxacin.

Authors:  Yukihiko Kato; Yu Sato; Miho Nakasu; Ryoji Tsuboi
Journal:  Allergy Asthma Clin Immunol       Date:  2018-04-03       Impact factor: 3.406

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.